Jia (Jenny) Liu, Translational Lead of Early Phase Drug Development at The Kinghorn Cancer Centre, shared a post on X:
“Fascinating ADC clinical trial plenary at AACR26.
Across EGFR and CLDN6 ADCs, target IHC expression alone failed to predict efficacy.
We are still selecting patients using a unidimensional biomarker for a multidimensional drug. Elegant discussion.”
More posts about AACR 2026.
